Publications by authors named "Elvira Canedo-Villaroya"
Clin Nutr ESPEN
October 2024
Article Synopsis
- The SCAN tool was developed to identify malnutrition risk in children with cancer but initially showed low effectiveness at diagnosing malnutrition during treatment.
- The study involved measuring various health indicators in 49 children diagnosed with cancer to validate the SCAN tool for predicting nutritional needs, toxicities, and treatment outcomes.
- While SCAN had improved effectiveness when applied periodically during treatment, the overall results indicated it couldn't reliably predict risk factors like relapse or survival rates.
Article Synopsis
- The study analyzes the outcomes of diagnosing inborn errors of metabolism (IEM) in newborns following the implementation of Expanded Newborn Screening from 2011 to 2019, where over 592,000 children were screened.
- Among those screened, 902 had abnormal results, and 222 confirmed cases of IEM were identified, including various conditions like aminoacidopathies, fatty acid oxidation (FAO) defects, and organic acidurias.
- Only 8.5% of the affected infants showed symptoms at the time of the newborn screening, and genetic testing confirmed the diagnosis in all except two cases of hyperphenylalaninemia (HPA).
Article Synopsis
- There is currently no standardized method for assessing nutrition in pediatric oncology patients, but the SCAN tool has been identified as a potentially effective screening option.
- This study evaluated the SCAN tool's validity and reliability in detecting malnutrition among newly diagnosed cancer patients at a pediatric hospital in Spain, including various assessments like blood markers and questionnaires.
- Results showed that 45% of patients were at risk of malnutrition, and while the SCAN tool is user-friendly, it may overlook some cases because it does not include measurements like weight and height, prompting the need for further research.
Article Synopsis
- Hyperammonemic encephalopathy is a serious side effect of the antiepileptic drug sodium valproate (VPA) observed in a study of 25 pediatric patients, primarily females aged around 7.6 years.
- The patients were treated with carglumic acid (CA), which effectively reduced elevated ammonia levels and resolved related symptoms over an average treatment duration of about 2.17 days.
- Despite the initial success of CA treatment, 68% of patients discontinued VPA, and 62% of those who continued VPA experienced recurrent hyperammonemia episodes.
